13.= more contracts for the infusion business, that would relieve dilution from future CR, complement our distribution business, add to earnings and valuation. A great company move would be to double or increase revenue by 50%. There is no point in leaving it as it is. It would increase our market share, maybe even buy a private company that has a bigger distribution business and consolidate operations and really launch the infusion side of things.
catalysts, page-3
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.56 |
Change
-0.740(5.56%) |
Mkt cap ! $265.4M | |||
| Open | High | Low | Value | Volume |
| $13.06 | $13.30 | $12.55 | $359.0K | 27.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 399 | $12.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.78 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |